

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

LAIR2 RABBIT PAB

货号: S219884 产品全名: LAIR2 兔多抗 基因符号 CD306

UNIPROT ID: Q6ISS4 (Gene Accession - NP_002279)

背景: The protein encoded by this gene is a member of the immunoglobulin superfamily. It was identified by its similarity to leukocyteassociated immunoglobulin-like receptor 1, a membrane-bound receptor that modulates innate immune response. The protein encoded by this locus is a soluble receptor that may play roles in both inhibition of collagen-induced platelet aggregation and vessel formation during placental implantation. This gene maps to a region of 19q13.4, termed the leukocyte receptor cluster, which contains 29 genes in the immunoglobulin superfamily. Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Sep 2013]

抗原: Synthetic peptide of human LAIR2

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 5000-10000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219884(LAIR2 Antibody) at a dilution of



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 219884(Anti-LAIR2 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffinembedded Human esophagus cancer tissue using 219884(Anti-LAIR2 Human esophagus cancer tissue is first treated with synthetic Antibody) at a dilution of 1/50.



In comparision with the IHC on the left, the same paraffin-embedded peptide and then with D260548(Anti-LAIR2 Antibody) at dilution 1/50.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010